Clinical Trial Information

Exelixis is conducting a comprehensive clinical program for the development of cabozantinib. To date, activity has been observed in multiple tumor types including regression of both soft tissue and bone metastases.

Phase Trial Description Tumor Types Covered Trial Information1
Phase 3 Efficacy of cabozantinib (XL184) in Advanced Medullary Thyroid Cancer (EXAM) Medullary Thyroid Cancer NCT00704730
Phase 2 Non-Randomized Extension Cohort (From RDT) Castration-Resistant Prostate Cancer NCT00940225
Phase 2 Non-Randomized Extension Cohort (From RDT) Ovarian Cancer NCT00940225
Phase 2 Randomized Discontinuation Trial (RDT)
Study of cabozantinib in Adults With Advanced Malignancies		 Breast Cancer
Gastric/GE Junctional Cancer
Hepatocellular Carcinoma
Melanoma
Castration-Resistant Prostate Cancer
Non-small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Small Cell Lung Cancer		 NCT00940225
Phase 1B Drug-Drug Interaction Safety Study Differentiated Thyroid Cancer Renal Cell Carcinoma NCT01100619

 

References:

  1. U.S. National Institutes of Health, ClinicalTrials.gov Web site: http://www.clinicaltrials.gov/